In today’s recent session, 0.46 million shares of the Castle Biosciences Inc (NASDAQ:CSTL) have been traded, and its beta is 1.02. Most recently the company’s share price was $26.17, and it changed around $4.32 or 19.75% from the last close, which brings the market valuation of the company to $722.42M. CSTL at last check was trading at a discount to its 52-week high of $25.91, offering almost 0.99% off that amount. The share price’s 52-week low was $12.07, which indicates that the recent value has risen by an impressive 53.88% since then. We note from Castle Biosciences Inc’s average daily trading volume that its 10-day average is 0.41 million shares, with the 3-month average coming to 331.73K.
Castle Biosciences Inc (NASDAQ:CSTL) trade information
Instantly CSTL has been showing a green trend so far today with a performance of 19.75% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 27.63 on recent trading dayincreased the stock’s daily price by 5.28%. The company’s shares are currently up 21.25% year-to-date, but still up 10.26% over the last five days. On the other hand, Castle Biosciences Inc (NASDAQ:CSTL) is 45.77% up in the 30-day period. We can see from the shorts that 1.81 million shares have been sold at a short interest cover period of 4.8 day(s).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target as assigned by Wall Street analysts is $41, which translates to bulls needing to increase their stock price by 36.17% from its current value. Analyst projections state that CSTL is forecast to be at a low of $41 and a high of $41.
Castle Biosciences Inc (CSTL) estimates and forecasts
Castle Biosciences Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 12.30 percent over the past six months and at a 22.43% annual growth rate that is well above the industry average of 16.30%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -150.00% in revenue this quarter, and will report a decrease of -490.00% in the next quarter. The year-over-year growth rate is expected to be 18.50%, up from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 57.63M in revenue for the current quarter. 9 analysts expect Castle Biosciences Inc to make 60.47M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 48.52M and 66.12M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 18.80%. Forecasts for the next quarter put sales growth at -8.50%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -28.57%.
CSTL Dividends
Castle Biosciences Inc’s next quarterly earnings report is expected to be released on 2024-Oct-31.
Castle Biosciences Inc (NASDAQ:CSTL)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.08% of Castle Biosciences Inc shares, and 98.30% of them are in the hands of institutional investors. The stock currently has a share float of 101.42%. Castle Biosciences Inc stock is held by 225.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-03-31, it held 9.603% of the shares, which is about 2.6 million shares worth $57.49 million.
WASATCH ADVISORS LP, with 9.438% or 2.55 million shares worth $56.51 million as of 2024-03-31, holds the second largest percentage of outstanding shares.
